MA31029B1 - Formes cristallines de glyt1 - Google Patents

Formes cristallines de glyt1

Info

Publication number
MA31029B1
MA31029B1 MA32049A MA32049A MA31029B1 MA 31029 B1 MA31029 B1 MA 31029B1 MA 32049 A MA32049 A MA 32049A MA 32049 A MA32049 A MA 32049A MA 31029 B1 MA31029 B1 MA 31029B1
Authority
MA
Morocco
Prior art keywords
crystalline forms
preparation
glyt1
rifluoro
psychoses
Prior art date
Application number
MA32049A
Other languages
English (en)
Inventor
Andre Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E Rohrer
Urs Schwitter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31029(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA31029B1 publication Critical patent/MA31029B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE QUATRE FORMES CRISTALLINES DISTINCTES ET UNE FORME AMORPHE DE [4-(3-FLUORO-5-TRIFLUOROMÉTHYL-PYRIDIN-2-YL)-PIPÉRAZIN-1-YL]-[5-MÉTHANESULFONYL-2-((S)-2,2,2-T RIFLUORO-1-MÉTHYL-ÉTHOXY)-PHÉNYL]-MÉTHANONE, ET LEUR UTILISATION POUR LA PRÉPARATION DE COMPOSITIONS PHARMACEUTIQUES. LES COMPOSÉS SELON LA PRÉSENTE INVENTION PEUVENT ÊTRE UTILISÉS POUR LA PRÉPARATION D'UN MÉDICAMENT UTILE POUR TRAITER LES PSYCHOSES, LA DOULEUR, LA DYSFONCTION NEURODÉGÉNÉRATIVE DE LA MÉMOIRE ET DE L'APPRENTISSAGE, LA SCHIZOPHRÉNIE, LA DÉMENCE ET D'AUTRES MALADIES DANS LESQUELLES LES PROCESSUS COGNITIFS SONT DÉTÉRIORÉS, PAR EXEMPLE LES TROUBLES DÉFICITAIRES DE L'ATTENTION OU LA MALADIE D'ALZHEIMER.
MA32049A 2006-12-28 2009-06-29 Formes cristallines de glyt1 MA31029B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28

Publications (1)

Publication Number Publication Date
MA31029B1 true MA31029B1 (fr) 2009-12-01

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32049A MA31029B1 (fr) 2006-12-28 2009-06-29 Formes cristallines de glyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (fr)
EP (1) EP2114405B1 (fr)
JP (1) JP4799666B2 (fr)
KR (1) KR101130146B1 (fr)
CN (1) CN101573114A (fr)
AR (1) AR064545A1 (fr)
AU (1) AU2007341356B2 (fr)
BR (1) BRPI0720829B8 (fr)
CA (1) CA2673667A1 (fr)
CL (1) CL2007003830A1 (fr)
CO (1) CO6190613A2 (fr)
CR (1) CR10846A (fr)
CY (1) CY1116350T1 (fr)
DK (1) DK2114405T3 (fr)
EC (1) ECSP099471A (fr)
ES (1) ES2535040T3 (fr)
HR (1) HRP20150573T1 (fr)
HU (1) HUE025032T2 (fr)
MA (1) MA31029B1 (fr)
MX (1) MX2009006859A (fr)
MY (1) MY188367A (fr)
NO (1) NO342150B1 (fr)
NZ (1) NZ577502A (fr)
PE (1) PE20081556A1 (fr)
PL (1) PL2114405T3 (fr)
PT (1) PT2114405E (fr)
RS (1) RS53910B1 (fr)
RU (1) RU2463295C2 (fr)
SI (1) SI2114405T1 (fr)
TW (1) TWI388552B (fr)
UA (1) UA100232C2 (fr)
WO (1) WO2008080821A1 (fr)
ZA (1) ZA200904423B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2114405E (pt) 2006-12-28 2015-06-02 Hoffmann La Roche Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
CN104334550A (zh) * 2012-05-25 2015-02-04 巴斯夫欧洲公司 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
CN116212025A (zh) 2020-01-09 2023-06-06 迪斯克医药公司 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
JP2024518091A (ja) * 2021-05-14 2024-04-24 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法
WO2022251458A1 (fr) * 2021-05-27 2022-12-01 Disc Medicine, Inc. Méthodes de traitement de la protoporphyrie érythropoïétique, de la protoporphyrie liée à l'x, ou de la porphyrie érythropoïétique congénitale avec une forme solide de bitopertine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI1656361T1 (sl) * 2003-08-11 2008-04-30 Hoffmann La Roche Piperazin z OR-substituirano fenilno skupino in njuna uporaba kot zaviralca GLYT1
PT2114405E (pt) 2006-12-28 2015-06-02 Hoffmann La Roche Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona

Also Published As

Publication number Publication date
CA2673667A1 (fr) 2008-07-10
TW200833677A (en) 2008-08-16
CO6190613A2 (es) 2010-08-19
DK2114405T3 (en) 2015-04-07
RS53910B1 (en) 2015-08-31
ES2535040T3 (es) 2015-05-04
ECSP099471A (es) 2009-07-31
BRPI0720829B1 (pt) 2020-04-07
MX2009006859A (es) 2009-07-03
KR101130146B1 (ko) 2012-03-28
US20130197225A1 (en) 2013-08-01
KR20090094166A (ko) 2009-09-03
US8039473B2 (en) 2011-10-18
RU2009124113A (ru) 2011-02-10
US20110295007A1 (en) 2011-12-01
AU2007341356A1 (en) 2008-07-10
HRP20150573T1 (en) 2015-07-03
UA100232C2 (uk) 2012-12-10
TWI388552B (zh) 2013-03-11
JP4799666B2 (ja) 2011-10-26
JP2010514725A (ja) 2010-05-06
AR064545A1 (es) 2009-04-08
MY188367A (en) 2021-12-06
NZ577502A (en) 2012-02-24
CL2007003830A1 (es) 2008-07-11
RU2463295C2 (ru) 2012-10-10
US20100311971A1 (en) 2010-12-09
US20120309969A1 (en) 2012-12-06
HUE025032T2 (en) 2016-02-29
CY1116350T1 (el) 2017-03-15
WO2008080821A1 (fr) 2008-07-10
US20080214561A1 (en) 2008-09-04
PT2114405E (pt) 2015-06-02
CR10846A (es) 2009-08-12
BRPI0720829B8 (pt) 2021-05-25
PL2114405T3 (pl) 2015-08-31
BRPI0720829A2 (pt) 2014-02-25
NO342150B1 (no) 2018-04-03
NO20092358L (no) 2009-06-22
EP2114405B1 (fr) 2015-03-11
PE20081556A1 (es) 2008-11-28
SI2114405T1 (sl) 2015-06-30
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (fr) 2009-11-11
ZA200904423B (en) 2010-05-26
CN101573114A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
MA31029B1 (fr) Formes cristallines de glyt1
MA27482A1 (fr) Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
TN2009000471A1 (fr) Composes amino-heterocycliques
MA27995A1 (fr) Piperazine avec groupe phenyle substitue de type or et leur utilisation comme inhibiteurs de glyt1
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
TW200502221A (en) Novel lactams and uses thereof
CA2433585A1 (fr) Compositions pharmaceutiques contenant du chlorhydrate de donepezil
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
WO2006040451A2 (fr) Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
MA27775A1 (fr) Composes organiques
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
MA29871B1 (fr) Composition pharmaceutique concue pour ameliorer la fonction cognitive
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
CA2501799A1 (fr) Composes pyrazole pour le traitement de maladies neurodegeneratives
WO2004085433A3 (fr) Modulateurs allosteriques positifs du recepteur nicotinique de l'acetylcholine
Messer Cholinergic agonists and the treatment of Alzheimer's disease
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
WO2005003103A3 (fr) Nouveaux heterocycles 2,4,6-trisubstitues et utilisations de ceux-ci
TNSN08138A1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques
JP7157471B2 (ja) （ｒ）－ジミラセタム（１）と（ｓ）－ジミラセタム（２）を非ラセミ比で含む相乗的組成物
TNSN05074A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
WO2005095348A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
TW200504036A (en) Novel lactams and uses thereof